Primary sclerosing cholangitis
ICD-10 K83.0 · ICD-11 DB96.2

Managing Osteoporosis and Osteopenia in Primary Sclerosing Cholangitis

Patients with primary sclerosing cholangitis (PSC) may develop concurrent metabolic bone disease. This protocol addresses PSC presenting alongside osteopenia or osteoporosis, conditions that require specific management in this hepatobiliary context.

Comorbidity
Treatment of metabolic bone disease in PSC is comparable to treatment for osteopenia and osteoporosis of any cause. Addressing bone health is an integral part of managing this patient population.
Treatment Goals
The primary clinical target is improvement in bone mineral density at the lumbar spine and femoral neck.
Approach Overview — partial
Management involves weight-bearing exercise alongside targeted supplementation as a first step; pharmacological intervention for established bone loss is also part of the structured regimen. The complete protocol specifies the full approach.
Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1038/ajg.2015.112

Treatment of metabolic bone disease in PSC is comparable to treatment for osteopenia and osteoporosis of any cause.

Patients are advised to undergo weight-bearing exercise and take calcium and vitamin D supplementation.

However, in patients with osteopenia and primary biliary cirrhosis, alendronate treatment has resulted in significant improvement in BMD, both at the lumbar spine and the femoral neck, suggesting that alendronate may be useful for treatment of osteopenia and osteoporosis in patients with PSC.

View source ↗